Core Viewpoint - The company plans to hold its first extraordinary shareholders' meeting in 2026 to discuss a proposal regarding capital increase in an associated company and related transactions [1] Group 1: Company Actions - The company intends to finance up to 150 million yuan for the associated company, Xianying Products, which it currently holds a 23.20% stake in [1] - The pre-investment valuation for this transaction is set at 450 million yuan, with the company planning to subscribe to an additional registered capital of 24 million yuan [1] - The lead investor for this transaction is Daoyuan Guosheng, with related parties Cao Jiaming and Huabo Instruments increasing their investments by 3.5 million yuan and 3 million yuan respectively, which constitutes a related transaction but does not qualify as a major asset restructuring [1]

Core Insights - The CRO (Contract Research Organization) industry in China is a strategic emerging industry that supports pharmaceutical innovation and is crucial for the transition from a pharmaceutical power to a pharmaceutical stronghold [1][9] - The development of policies for the CRO industry has evolved from a focus on the overall biopharmaceutical sector to specialized areas, emphasizing innovation, safety, and supply chain security [1][3] Policy Development History - The policy evolution from the "Tenth Five-Year Plan" to the "Fourteenth Five-Year Plan" has progressively recognized the importance of the CRO industry, with increasing support for specialized services [1] - The "Fifteenth Five-Year Plan" emphasizes differentiated, high-value innovation alongside supply chain security [1] National Policy Summary and Interpretation - Since 2006, multiple national policies have been introduced to support the CRO service system, focusing on regulatory standards, clinical trial optimization, and international development [3][7] - Key policies include the establishment of the MAH (Marketing Authorization Holder) system and the optimization of review and approval processes [3][7] Key National Policies (2025 Outlook) - Policies from 2006 to 2025 highlight the strategic importance of biopharmaceuticals and the CRO industry, with a focus on enhancing innovation capabilities and regulatory frameworks [4][5][6] - Recent policies aim to streamline clinical trial approvals and support the development of innovative drugs [6][10] Provincial and Municipal Policy Summary - Various provinces and cities have implemented supportive policies for the CRO industry, including investment subsidies, revenue rewards, and insurance subsidies, with some regions offering up to 50 million yuan in support [11][12] - Specific measures include allowing foreign investment in CROs and promoting AI integration in the industry [11][12][14] Provincial Development Goals - Regions like the Yangtze River Delta focus on high-end CRO service systems, while the Beijing-Tianjin-Hebei area emphasizes collaborative innovation and full-chain outsourcing [14] - Local governments aim to enhance the scale and service capabilities of the biopharmaceutical industry, with targeted initiatives for specific sectors such as seed industry CROs in Hainan [14]

Group 1 - The core point of the article is that Chengdu XianDao plans to invest 24 million yuan in a stake in XianYan Biological, with a pre-investment valuation of 450 million yuan. XianYan focuses on the development of small nucleic acid new drugs, with its hypertension drug LDR2402 entering Phase II clinical trials and the obesity drug LDR2515 recently receiving implied permission for clinical trials. The investment round is led by Daoyuan Guosheng, with a total financing amount not exceeding 150 million yuan, and Chengdu XianDao's shareholding will be adjusted based on the financing results [1] Group 2 - In the recent stock performance, Chengdu XianDao's stock price fluctuated between 29.84 yuan and 30.26 yuan over the past week, with a range of 13.48%. The capital flow indicates a divergence in main funds, with a net inflow of 45.28 million yuan on February 10, followed by a net outflow of 12.56 million yuan on February 11. As of February 12, the turnover rate was 2.04%, with a single-day increase of 1.44% [2]

Core Viewpoint - The report from Guolian Minsheng Securities highlights the synergistic effects of small nucleic acid drugs and GLP-1 class drugs in the weight loss sector, suggesting they could become a "golden duo" for weight management [1][4]. Group 1: Drug Efficacy and Development - Arrowhead has reported promising initial weight loss results from two small nucleic acid drugs targeting INHBE and ALK7, with ARO-INHBE showing an average fat reduction of 9.9% and liver fat reduction of up to 38.6%, alongside a 3.6% increase in lean tissue [1]. - ARO-ALK7 demonstrated a dose-dependent average reduction of ALK7 mRNA by 88%, confirming the TRiM platform's ability to inhibit fat cell gene expression [1]. - Wave Life's WVE-007 targeting liver INHBE showed a 9.4% reduction in visceral fat and a 4.5% overall fat reduction after three months, with a 3.2% increase in lean body mass [3]. Group 2: Market Trends and Collaborations - Major pharmaceutical companies are increasingly investing in small nucleic acid drugs, with Eli Lilly committing $1.2 billion in collaboration with Saint Inbiotech for RNAi candidate drug development for metabolic diseases [3]. - Eli Lilly also invested $1 billion in HAYA's lncRNA platform for obesity and related metabolic disease treatments, while Novo Nordisk partnered with Replicate Bioscience for a $550 million project targeting obesity and type 2 diabetes [3]. - The speed of Chinese pharmaceutical companies in developing small nucleic acid drugs for weight loss is nearly on par with international counterparts, with several companies like Hengrui Medicine and Innovent Biologics actively pursuing this area [5]. Group 3: Investment Recommendations - The report suggests focusing on companies involved in small nucleic acid weight loss targets, including Hengrui Medicine, Chengdu Xian Dao, China National Pharmaceutical Group, East China Pharmaceutical, and others [6].

Group 1 - The company, Chengdu XianDao Pharmaceutical Development Co., Ltd., will hold its first extraordinary general meeting of shareholders in 2026 on March 2, 2026, at 14:00 [1][4] - The meeting will be conducted using a combination of on-site and online voting methods [1][3] - The on-site meeting will take place at the company's office located in Chengdu, Sichuan Province [1][4] Group 2 - The online voting system will be provided by the Shanghai Stock Exchange, with voting available from 9:15 to 15:00 on the day of the meeting [2][3] - Shareholders must register to attend the meeting by submitting required documents by February 27, 2026 [12][14] - The company will disclose meeting materials on the Shanghai Stock Exchange website prior to the meeting [4] Group 3 - There are no special resolutions or proposals for minority shareholders to vote separately [5] - Certain related shareholders are required to abstain from voting on specific proposals [5] - The meeting will be attended by registered shareholders, company directors, senior management, and appointed lawyers [8][9]

证券代码：688222 证券简称：成都先导 公告编号：2026-006 成都先导药物开发股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 召开日期时间：2026 年 3 月 2 日 14 点 00 分 召开地点：成都市双流区慧谷东一路 8 号天府国际生物城 C2 栋成都先导药 物开发股份有限公司二楼大会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 3 月 2 日 至2026 年 3 月 2 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东会召开日期：2026年3月2日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日 ...

Group 1 - The core point of the article is that Chengdu XianDao (688222) plans to invest 24 million yuan in Chengdu XianYan Biological Technology Co., Ltd. at a pre-investment valuation of 450 million yuan [2] - Chengdu XianYan is a subsidiary and related party of Chengdu XianDao, with a registered capital of 17.2408 million yuan, and aims to raise no more than 150 million yuan for its development [2] - The company has established an innovative technology system including novel small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology, focusing on chronic disease treatment [2] Group 2 - The investment will increase Chengdu XianDao's stake in Chengdu XianYan, which currently holds 23.2% of the equity, with the final ownership percentage to be determined based on the total financing amount and the new registered capital [2]

证券代码：688222 证券简称：成都先导 公告编号：2026-005 成都先导药物开发股份有限公司 关于增资参股公司暨关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 至本公告披露日，成都先导药物开发股份有限公司（以下简称"成都 先导"或"公司"）过去 12 个月与同一关联人先衍生物进行的日常关联交易金 额为 1,287.44 万元，未超过董事会审议的日常关联交易金额；与本次交易累 计已达到股东会审议标准，尚需提交公司股东会审议。 公司过去 12 个月与关联方曹家铭、拉萨经济技术开发区华博医疗器械有 限公司（以下简称"华博器械"）均未发生关联交易。 交易实施尚需履行的审批及其他相关程序 本次关联交易已经公司第三届董事会第五次会议审议通过，关联董事已回避 表决。独立董事专门会议对本次交易事项进行了事先审议，全体独立董事一致同 意该交易事项。本次关联交易事项达到股东会审议标准，尚需提交股东会审议。 其它需要提醒投资者重点关注的风险事项 本次对参股企业先衍生物增资，各方均在履行内部签约流程，尚未完成实际 ...

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan Biotech, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan Biotech has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The company is advancing its drug pipeline with LDR2402, a long-acting antihypertensive drug targeting AGT, which has entered Phase II clinical trials and completed the first dosing of a subject [1] - An IND application for LDR2515, a small nucleic acid drug for obesity treatment targeting INHBE, has received implied approval from the CDE [1] Group 2: Financial and Investment Details - Chengdu XianDao plans to invest up to 15 million yuan in XianYuan Biotech, which has a registered capital of 17.24 million yuan [1] - Prior to this transaction, Chengdu XianDao held a 23.20% stake in XianYuan Biotech and intends to subscribe to an additional capital increase of 24 million yuan based on a pre-investment valuation of 450 million yuan [1] - The lead investor in this financing round is Chengdu TianShi DaoYuan GuoSheng Medical Health Venture Capital Partnership, with other investors including related parties [1]

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The ultra-long-acting antihypertensive drug LDR2402 targeting the AGT site has entered Phase II clinical trials, with the first subject already dosed [1] - The clinical trial application (IND) for the small nucleic acid new drug LDR2515 injection (targeting INHBE) for obesity treatment has recently received implied approval from the China National Medical Products Administration (CDE) [1] Group 2: Financing and Shareholding - XianYuan is a subsidiary and affiliated party of Chengdu XianDao, with a registered capital of 17.24 million yuan [1] - Chengdu XianDao plans to subscribe to an additional registered capital of 24 million yuan at a pre-investment valuation of 450 million yuan, increasing its shareholding in XianYuan from 23.20% [1] - The lead investor in this financing round is Chengdu Angel DaoYuan GuoSheng Medical Health Venture Capital Partnership (Limited Partnership), with other investors including affiliated parties Cao Jiaming and Huabo Medical [1]